Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from enVVeno Medical ( (NVNO) ) is now available.
On May 19, 2025, enVVeno Medical Corporation appointed Jennifer Bright as its new Chief Financial Officer. Ms. Bright, a seasoned certified public accountant with over 25 years of experience, previously served as CFO at BIOLASE, Inc. Her appointment comes with an employment agreement that includes a $300,000 annual salary, potential bonuses, stock options, and participation in company benefit plans. Concurrently, Craig Glynn resigned as CFO but will continue to assist the company through a consulting agreement to ensure a smooth transition.
Spark’s Take on NVNO Stock
According to Spark, TipRanks’ AI Analyst, NVNO is a Neutral.
enVVeno Medical’s overall stock score is influenced by its robust technical performance, which is somewhat overshadowed by challenging financial metrics. The company faces significant profitability issues, as reflected by its negative income and cash flow figures, despite having a stable balance sheet. While technical indicators show strong upward momentum, valuation concerns due to a negative P/E ratio and lack of dividends weigh on the score.
To see Spark’s full report on NVNO stock, click here.
More about enVVeno Medical
Average Trading Volume: 88,732
Technical Sentiment Signal: Hold
Current Market Cap: $63.66M
See more data about NVNO stock on TipRanks’ Stock Analysis page.